Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) Director Kathleen Mcgroddy-Goetz bought 1,000 shares of Tandem Diabetes Care stock in a transaction dated Friday, September 15th. The stock was purchased at an average price of $21.45 per share, for a total transaction of $21,450.00. Following the purchase, the director now directly owns 9,032 shares in the company, valued at approximately $193,736.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Tandem Diabetes Care Trading Down 0.5 %
Tandem Diabetes Care stock traded down $0.11 during trading hours on Tuesday, reaching $22.03. 1,314,146 shares of the company’s stock traded hands, compared to its average volume of 1,301,898. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.53 and a current ratio of 4.38. Tandem Diabetes Care, Inc. has a fifty-two week low of $21.01 and a fifty-two week high of $58.82. The firm’s 50 day moving average is $28.93 and its 200-day moving average is $32.01.
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last posted its quarterly earnings results on Thursday, August 3rd. The medical device company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.24. Tandem Diabetes Care had a negative net margin of 28.40% and a negative return on equity of 20.29%. The business had revenue of $195.92 million during the quarter, compared to the consensus estimate of $201.62 million. As a group, research analysts forecast that Tandem Diabetes Care, Inc. will post -1.49 earnings per share for the current year.
Analysts Set New Price Targets
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in TNDM. Belpointe Asset Management LLC acquired a new position in Tandem Diabetes Care in the fourth quarter valued at about $26,000. GPS Wealth Strategies Group LLC bought a new stake in shares of Tandem Diabetes Care in the 1st quarter valued at about $27,000. AdvisorNet Financial Inc bought a new stake in shares of Tandem Diabetes Care in the 2nd quarter valued at about $37,000. State of Wyoming raised its position in shares of Tandem Diabetes Care by 45.8% in the 4th quarter. State of Wyoming now owns 821 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 258 shares during the period. Finally, Quadrant Capital Group LLC boosted its stake in Tandem Diabetes Care by 53.5% during the 4th quarter. Quadrant Capital Group LLC now owns 841 shares of the medical device company’s stock worth $38,000 after acquiring an additional 293 shares during the last quarter.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
- Five stocks we like better than Tandem Diabetes Care
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Hold-It-Forever AutoZone Pulls into Buy Zone
- How to Invest in Insurance Companies: A Guide
- Virtual Riches: 3 Stocks Leading the VR Revolution
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.